Prazosin ops Tablet
Description
PRAZOLET-2.5 XL
Prazosin 2.5 mg Extended-Release Tablets
Division: DIABGLYM
Composition
Each extended-release tablet contains:
Prazosin IP — 2.5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Extended-release oral tablet
Product Description
PRAZOLET-2.5 XL contains Prazosin 2.5 mg in an extended-release formulation, designed for the effective management of hypertension and conditions associated with increased peripheral vascular resistance. Prazosin is a selective alpha-1 adrenergic receptor blocker that promotes vasodilation, reduces peripheral vascular resistance, and helps lower blood pressure without significantly affecting cardiac output.
The extended-release formulation provides sustained drug release, helping maintain stable plasma concentrations and prolonged blood pressure control throughout the day. Prazosin is widely used in cardiology, internal medicine, and vascular medicine for patients with essential hypertension, resistant hypertension, and hypertension associated with diabetes, metabolic syndrome, or vascular disorders.
PRAZOLET-2.5 XL is particularly beneficial for patients requiring gradual blood pressure reduction, sustained antihypertensive action, improved peripheral circulation, and long-term cardiovascular management.
Technical Knowledge of Prazosin
Prazosin selectively blocks post-synaptic alpha-1 adrenergic receptors located in arterioles and veins. This inhibition reduces sympathetic-mediated vasoconstriction, resulting in arterial and venous dilation, decreased systemic vascular resistance, reduced preload and afterload, and improved peripheral blood flow.
The extended-release formulation allows controlled drug delivery over an extended period, reducing fluctuations in plasma concentration and providing consistent antihypertensive activity with convenient once-daily administration.
Mechanism of Action
Prazosin selectively blocks alpha-1 adrenergic receptors, relaxes vascular smooth muscle, reduces peripheral vascular resistance, decreases arterial and venous tone, lowers blood pressure, and improves peripheral circulation.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Sustained extended-release antihypertensive action
Reduces peripheral vascular resistance
Improves peripheral blood circulation
Supports gradual blood pressure control
Provides convenient once-daily dosing
Enhances patient compliance
Suitable for long-term hypertension management under medical supervision
Clinical Applications
PRAZOLET-2.5 XL is commonly prescribed for essential hypertension, resistant hypertension, hypertension associated with diabetes, hypertension with peripheral vascular disease, Raynaud’s phenomenon, and long-term cardiovascular risk management.
Facts About Prazosin
Prazosin is a well-established alpha-1 adrenergic blocker with proven efficacy in reducing peripheral vascular resistance and improving blood pressure control. The extended-release formulation provides prolonged therapeutic activity, improved patient adherence, and more consistent antihypertensive efficacy. It is also recognized for its beneficial effects on peripheral circulation and vascular function.
Key Facts
Selective alpha-1 adrenergic blocker
Prazosin 2.5 mg extended-release formulation
Provides sustained blood pressure control
Improves peripheral vascular circulation
Supports long-term cardiovascular management
Evidence-based antihypertensive therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
PRAZOLET-2.5 XL is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, metabolic syndrome, peripheral vascular disorders, and cardiovascular disease creates strong prescription demand and long-term market potential for this formulation.
Why Choose PRAZOLET-2.5 XL for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Prazosin 2.5 mg Extended-Release Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented extended-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
PRAZOLET-2.5 XL from DIABGLYM combines sustained blood pressure control, improved peripheral circulation, evidence-based alpha-blocker therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and advanced Prazosin formulation.
